News

News From Roche Pharmaceuticals In New Zealand

17 Jun 2009
Hundreds of New Zealanders to benefit from PHARMAC funding for cancer

New Zealanders diagnosed with indolent (low grade) non Hodgkin’s lymphoma (NHL) now have expanded funding for a cutting edge biotherapy, MabThera® (rituximab), increasing their chances of beating this slowly progressing but often fatal disease.

19 May 2009
Hundreds could benefit as treatment gains registration for new use

Widened access to a leading-edge biotherapy has given hope to hundreds of New Zealanders diagnosed with chronic lymphocytic leukaemia (CLL), a stubbornly incurable form of white blood cell cancer.

2 Apr 2009
Experts say new PHARMAC funding could help avert potential public health ‘time bomb’

Health experts believe that new access to Pegasys® (peginterferon alfa-2a (40KD)), an effective antiviral treatment for two diseases, chronic hepatitis B and C, today announced by PHARMAC, will save thousands of lives and hundreds of millions of taxpayer dollars over the next twenty years.

Medicines
For more information about Roche prescription medicines, click here.

International News
For Roche International news click here.

Background Information
For background information on Roche disease areas, current treatment and global statistics, please visit the Roche Health Kiosk.